174 related articles for article (PubMed ID: 31324954)
1. Bone-Bound Bisphosphonates Inhibit Proliferation of Breast Cancer Cells.
Park YE; Bava U; Lin JM; Cornish J; Naot D; Reid IR
Calcif Tissue Int; 2019 Nov; 105(5):497-505. PubMed ID: 31324954
[TBL] [Abstract][Full Text] [Related]
2. Bone-bound bisphosphonate inhibits growth of adjacent non-bone cells.
Cornish J; Bava U; Callon KE; Bai J; Naot D; Reid IR
Bone; 2011 Oct; 49(4):710-6. PubMed ID: 21807133
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of the mevalonate pathway and activation of p38 MAP kinase are independently regulated by nitrogen-containing bisphosphonates in breast cancer cells.
Merrell MA; Wakchoure S; Lehenkari PP; Harris KW; Selander KS
Eur J Pharmacol; 2007 Sep; 570(1-3):27-37. PubMed ID: 17640631
[TBL] [Abstract][Full Text] [Related]
4. Distinct mechanisms of bisphosphonate action between osteoblasts and breast cancer cells: identity of a potent new bisphosphonate analogue.
Reinholz GG; Getz B; Sanders ES; Karpeisky MY; Padyukova NSh; Mikhailov SN; Ingle JN; Spelsberg TC
Breast Cancer Res Treat; 2002 Feb; 71(3):257-68. PubMed ID: 12002344
[TBL] [Abstract][Full Text] [Related]
5. Extracellular calcium increases bisphosphonate-induced growth inhibition of breast cancer cells.
Journé F; Kheddoumi N; Chaboteaux C; Duvillier H; Laurent G; Body JJ
Breast Cancer Res; 2008; 10(1):R4. PubMed ID: 18190680
[TBL] [Abstract][Full Text] [Related]
6. Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone.
Ottewell PD; Woodward JK; Lefley DV; Evans CA; Coleman RE; Holen I
Mol Cancer Ther; 2009 Oct; 8(10):2821-32. PubMed ID: 19789217
[TBL] [Abstract][Full Text] [Related]
7. Bisphosphonates induce breast cancer cell death in vitro.
Fromigue O; Lagneaux L; Body JJ
J Bone Miner Res; 2000 Nov; 15(11):2211-21. PubMed ID: 11092402
[TBL] [Abstract][Full Text] [Related]
8. Zoledronic acid induces apoptosis and changes the TRAIL/OPG ratio in breast cancer cells.
Rachner TD; Singh SK; Schoppet M; Benad P; Bornhäuser M; Ellenrieder V; Ebert R; Jakob F; Hofbauer LC
Cancer Lett; 2010 Jan; 287(1):109-16. PubMed ID: 19577359
[TBL] [Abstract][Full Text] [Related]
9. Bisphosphonate-induced ATP analog formation and its effect on inhibition of cancer cell growth.
Mönkkönen H; Kuokkanen J; Holen I; Evans A; Lefley DV; Jauhiainen M; Auriola S; Mönkkönen J
Anticancer Drugs; 2008 Apr; 19(4):391-9. PubMed ID: 18454049
[TBL] [Abstract][Full Text] [Related]
10. Expression of matrix macromolecules and functional properties of breast cancer cells are modulated by the bisphosphonate zoledronic acid.
Dedes PG; Gialeli Ch; Tsonis AI; Kanakis I; Theocharis AD; Kletsas D; Tzanakakis GN; Karamanos NK
Biochim Biophys Acta; 2012 Dec; 1820(12):1926-39. PubMed ID: 22884656
[TBL] [Abstract][Full Text] [Related]
11. Differential effects of Ca(2+) on bisphosphonate-induced growth inhibition in breast cancer and mesothelioma cells.
Merrell MA; Wakchoure S; Ilvesaro JM; Zinn K; Gehrs B; Lehenkari PP; Harris KW; Selander KS
Eur J Pharmacol; 2007 Mar; 559(1):21-31. PubMed ID: 17214981
[TBL] [Abstract][Full Text] [Related]
12. Removal of matrix-bound zoledronate prevents post-extraction osteonecrosis of the jaw by rescuing osteoclast function.
Elsayed R; Abraham P; Awad ME; Kurago Z; Baladhandayutham B; Whitford GM; Pashley DH; McKenna CE; Elsalanty ME
Bone; 2018 May; 110():141-149. PubMed ID: 29408511
[TBL] [Abstract][Full Text] [Related]
13. VEGFA Involves in the Use of Fluvastatin and Zoledronate Against Breast Cancer.
Pu H; Zhang Q; Zhao C; Shi L; Wang Y; Wang J; Zhang M
Pathol Oncol Res; 2018 Jul; 24(3):557-565. PubMed ID: 28744693
[TBL] [Abstract][Full Text] [Related]
14. Breast cancer cells inhibit spontaneous and bisphosphonate-induced osteoclast apoptosis.
Hussein O; Tiedemann K; Komarova SV
Bone; 2011 Feb; 48(2):202-11. PubMed ID: 20849994
[TBL] [Abstract][Full Text] [Related]
15. Preventive effects of zoledronic acid on bone metastasis in mice injected with human breast cancer cells.
Jeong J; Lee KS; Choi YK; Oh YJ; Lee HD
J Korean Med Sci; 2011 Dec; 26(12):1569-75. PubMed ID: 22147993
[TBL] [Abstract][Full Text] [Related]
16. Low-intensity continuous ultrasound triggers effective bisphosphonate anticancer activity in breast cancer.
Tardoski S; Ngo J; Gineyts E; Roux JP; Clézardin P; Melodelima D
Sci Rep; 2015 Nov; 5():16354. PubMed ID: 26578234
[TBL] [Abstract][Full Text] [Related]
17. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel.
Jagdev SP; Coleman RE; Shipman CM; Rostami-H A; Croucher PI
Br J Cancer; 2001 Apr; 84(8):1126-34. PubMed ID: 11308265
[TBL] [Abstract][Full Text] [Related]
18. Synergistic suppression of human breast cancer cells by combination of plumbagin and zoledronic acid In vitro.
Qiao H; Wang TY; Yan W; Qin A; Fan QM; Han XG; Wang YG; Tang TT
Acta Pharmacol Sin; 2015 Sep; 36(9):1085-98. PubMed ID: 26235741
[TBL] [Abstract][Full Text] [Related]
19. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite.
Nancollas GH; Tang R; Phipps RJ; Henneman Z; Gulde S; Wu W; Mangood A; Russell RG; Ebetino FH
Bone; 2006 May; 38(5):617-27. PubMed ID: 16046206
[TBL] [Abstract][Full Text] [Related]
20. Combined inhibition of the mevalonate pathway with statins and zoledronic acid potentiates their anti-tumor effects in human breast cancer cells.
Göbel A; Thiele S; Browne AJ; Rauner M; Zinna VM; Hofbauer LC; Rachner TD
Cancer Lett; 2016 May; 375(1):162-171. PubMed ID: 26968247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]